Verastem (VSTM) Times Interest Earned (2017 - 2026)
Verastem's quarterly Times Interest Earned came in at -$117.53 in Q1 2026, up 48.92% year-on-year from -$78.92 in Q1 2025, and down 157.61% quarter-over-quarter from $204.01 in Q4 2025.
Verastem has reported Times Interest Earned for 10 years, with the latest figure at -$117.53 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 48.92% year-over-year to -$117.53; the trailing twelve-month figure through Mar 2026 stood at -$36.77 (down 1.66% YoY), and the FY2025 full-year result was -$38.65, down 53.4% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$117.53, down from $204.01 in the prior quarter.
- The five-year high for Times Interest Earned was $204.01 in Q4 2025, with the low at -$437.64 in Q2 2025.
- Average Times Interest Earned over 5 years is -$75.54, with a median of -$27.57 recorded in 2024.
- Peak annual rise in Times Interest Earned reached 840.1% in 2025, while the deepest fall reached 2624.92% in 2025.
- Tracing VSTM's Times Interest Earned over 5 years: stood at -$23.27 in 2022, then decreased by 19.49% to -$27.8 in 2023, then climbed by 0.85% to -$27.57 in 2024, then jumped by 840.1% to $204.01 in 2025, then tumbled by 157.61% to -$117.53 in 2026.
- The last three Times Interest Earned figures came in at -$117.53 (Q1 2026), $204.01 (Q4 2025), and -$127.63 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | -117.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.53 |
| Dec 31, 2025 | 204.01 |
| Sep 30, 2025 | -127.63 |
| Jun 30, 2025 | -437.64 |
| Mar 31, 2025 | -230.07 |
| Dec 31, 2024 | -27.57 |
| Sep 30, 2024 | -32.26 |
| Jun 30, 2024 | -16.06 |
| Mar 31, 2024 | -24.83 |
| Dec 31, 2023 | -27.80 |
| Sep 30, 2023 | -18.87 |
| Jun 30, 2023 | -18.10 |
| Mar 31, 2023 | -25.15 |
| Dec 31, 2022 | -23.27 |
| Sep 30, 2022 | -24.70 |
| Jun 30, 2022 | -33.44 |
| Mar 31, 2022 | -303.21 |
| Dec 31, 2021 | -1,651.10 |
| Sep 30, 2021 | -1.86 |
| Jun 30, 2021 | -15.83 |
| Mar 31, 2021 | -14.47 |
| Dec 31, 2020 | -12.37 |
| Sep 30, 2020 | 7.91 |
| Jun 30, 2020 | -11.38 |
| Mar 31, 2020 | -2.47 |
| Dec 31, 2019 | -6.11 |
| Sep 30, 2019 | -5.18 |
| Jun 30, 2019 | -7.38 |
| Mar 31, 2019 | -7.03 |
| Dec 31, 2018 | -8.67 |
| Sep 30, 2018 | -25.02 |
| Jun 30, 2018 | -35.26 |
| Mar 31, 2018 | -43.25 |
| Dec 31, 2017 | -55.04 |
| Sep 30, 2017 | -210.34 |
| Jun 30, 2017 | -123.55 |
| Mar 31, 2017 | -1,095.67 |